Novel Conjugation of Tumor‐Necrosis‐Factor‐Related Apoptosis‐Inducing Ligand (TRAIL) with Monomethyl Auristatin E for Efficient Antitumor Drug Delivery
Li-Qiang Pan,Hai-Bin Wang,Zhang-Ming Xie,Zhao-Hui Li,Xiao-Jing Tang,Ying-Chun Xu,Chen Zhang,Hua Naranmandura,Shu-Qing Chen
DOI: https://doi.org/10.1002/adma.201301385
IF: 29.4
2013-01-01
Advanced Materials
Abstract:Monomethyl auristatin E (MMAE) is conjugated with TNF-related apoptosis-inducing ligand (TRAIL) via a linker that is stable in extracellular fluid, while it is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism of MMAE. The TRAIL-MMAE conjugate is a conceptually viable therapeutic strategy with improved in vitro antitumor activity, cell circle arrest and specific accumulation in tumor to treat TRAIL-resistant tumors.
What problem does this paper attempt to address?